General Description
Artemether 40mg + Lumefantrine 240mg fixed dose combination tablets,
blister strip of 12 tablets, pack of 1
Technical specifications
Each tablet contains Artemether 40mg Ph. Int. and Lumefantrine 240mg
Tablets are scored with at least one break line to allow for division of
tablets into two parts, each containing the same amount of active
ingredients.
Therapeutic class
Artemether is an artemesinin derivative
Lumefantrine is a synthetic racemic fluorene mixture
Standard shelf life
2 years (24 months)
Other available formulations
Artemether 20mg + Lumefantrine 120mg tablets, 6s, 18s, 24s
Artemether 20mg + Lumefantrine 120mg dispersible tablets 6s, 12s
Artemether injection 20mg/ml, 40mg/ml, 80mg/ml, 100mg/ml
Artemotil 50mg/ml, 75mg/ml, 150mg/ml
Artemether 40mg+Lumefantrine 240mg tablets 6s, 12s
Artemether 80mg+Lumefantrine 480mg tablets 6s (Not yet available from
UNICEF)
Artesunate injection 60mg (Not yet available from UNICEF)
Artemether 15mg/5ml+Lumefantrine 90mg/5ml oral suspension (Not yet
available from UNICEF)
Indications
Treatment of acute uncomplicated malaria caused by P. falciparum alone
or with other Plasmodium spp. In areas with significant drug resistance:
By Mouth (PO)
Dosage
Suggested dosing is based on the WHO guidelines for the treatment of
Malaria: www.who.int/malaria/publications/atoz/9241546948/en/index.html
Temperature considerations
Do not store above 30 °C (86 °F)
Storage
Store at temperatures not exceeding 30 °C (86 °F).
Keep out of the reach and sight of children
Dispensing instructions
Dispense in original container. Do not repack
Lumefantrine absorption is enhanced by co-administration with fat.
Patients with acute malaria are often averse to food, therefore, they
should be encouraged to resume intake as soon as they can tolerate food
to improve absorption. Advice patients or carers of the need to take AL
with milk or fat-containing food, particularly on the second (2nd) and
third (3rd) day of treatment.
Advice patient to repeat dose if vomiting occurs within one hour of
taking the last dose.
Guidelines for use
For more details, please see
World Health Organisation (WHO), Guidelines for the treatment of
Malaria: (www.who.int/malaria/en/)
WHO, Model Lists of Essential Medicines for adults and/or children
respectively:
(www.who.int/medicines/publications/essentialmedicines/en/index.html)
WHO Model Formulary: (apps.who.int/emlib/Default.aspx?Language=EN)
or your regional and/or national guidelines.
to top
|